Authors


Raveen Syan, MD, FPMRS

Latest:

Raveen Syan, MD, shares 2025 Urology on the Beach highlights

"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive bladder," says Raveen Syan, MD, FPMRS.


Petros Grivas, MD, PhD

Latest:

Frontline Therapy for Non-Metastatic Muscle-Invasive Bladder Cancer

Frontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.


Camillo Porta, MD

Latest:

Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma

"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.


Tullika Garg, MD, MPH, FACS

Latest:

Managing aging and frailty in the urologic cancer population

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.


Ronney Abaza, MD, FACS

Latest:

Ronney Abaza, MD, FACS, on what’s coming down the pike in robotic surgery

“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.


Jordyn Sava

Latest:

Cretostimogene grenadenorepvec made available through expanded access program

Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.


Andrew Y. Sun, MD

Latest:

Pearls & Perspectives: Updates in testosterone therapy, with Andrew Sun, MD at AUA 2025

Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.



Dylann Cohn-Emery

Latest:

Investigational HIF-2α inhibitor shows activity, safety in advanced clear cell RCC

This monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.


Jacob E. Tallman, MD

Latest:

Update on advanced imaging in prostate cancer

Advances allow for more accurate detection of metastatic disease.


Martin G. Sanda, MD

Latest:

Martin Sanda, MD, considers potential future advancements in urology

According to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration.



Amy N. Luckenbaugh, MD

Latest:

The emotional toll of surgical complications on urologic surgeons

"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.


Garrett D. Pohlman, MD

Latest:

We got a little MIST-y at this year’s AUA Annual Meeting

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.


Kamal S. Pohar, MD

Latest:

Lymph nodes in bladder cancer: Past, present, and future

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.


Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO

Latest:

Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation Therapy

Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.


Arpeet Shah, MD

Latest:

Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025

Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.


Joseph M. Jacob, MD, MCR

Latest:

Joseph Jacob, MD, on the durability of TAR-200 in NMIBC

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.


Ammad Khan, MD

Latest:

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.


Brendan M. Browne, MD

Latest:

Brendan Browne, MD, on patient selection for HoLEP for BPH

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder failure,” says Brendan M. Browne, MD.


Caitlin Shepherd, MD

Latest:

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.


AACU

Latest:

AACU 2024 Advocacy Summit & Annual Meeting

This year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.


Anna Myers, CNP

Latest:

Urology CNP discusses sensitivity in communication, physical exam

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP.


Eugene B. Cone, MD

Latest:

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.


James C. Ulchaker, MD

Latest:

Expert discusses the promise of emerging MISTs for BPH

James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.


Mary K. Samplaski, MD
Mary K. Samplaski, MD

Latest:

Expert Forum: Fertility after exogenous testosterone replacement

Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.


Hiten D. Patel, MD, MPH

Latest:

Distinguishing between malignant and benign renal masses

"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.


Anne K. Schuckman, MD

Latest:

What determines the optimal urinary diversion?

"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.


Daniel P. Petrylak, MD

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.


Daniel D. Rhoads, MD

Latest:

Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.

© 2025 MJH Life Sciences

All rights reserved.